House Resolution
H.Res. 803
Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.
Primary Sponsor
John Rose
R - TN
Cosponsors
11
Quick Stats
Policy Area
Summary
Urges the FDA to reevaluate the safety of mifepristone and other chemical abortion drugs, citing independent studies claiming complication rates 22 times higher than officially reported. Notes chemical abortions now account for over half of U.S. abortions.
Latest Action
Referred to the House Committee on Energy and Commerce.
See this page through your district lens
Enter ZIP to personalize representatives and vote context.
Stay on top of this issue
Subscribe for weekly bill and representative updates.
Vote Prediction
Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.
Urges the FDA to reevaluate the safety of mifepristone and other chemical abortion drugs, citing independent studies claiming complication rates 22 times higher than officially reported. Notes chemical abortions now account for over half of U.S. abortions.
Community Breakdown
Pass
0%
Fail
0%
0 predictions
Urges the FDA to reevaluate the safety of mifepristone and other chemical abortion drugs, citing independent studies claiming complication rates 22 times higher than officially reported. Notes chemical abortions now account for over half of U.S. abortions.
- Bill Number
- 803
- Introduced
- 10/10/2025
- Status
- Referred to the House Committee on Energy and Commerce.
- Policy Area
- Health
Data from Congress.gov
Fact Sheet
- Title
- Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.
- Bill Number
- 803
- Sponsor
- No sponsor
- Status
- Referred to the House Committee on Energy and Commerce.
- Introduced
- 10/10/2025
- Summary
- Urges the FDA to reevaluate the safety of mifepristone and other chemical abortion drugs, citing independent studies claiming complication rates 22 times higher than officially reported. Notes chemical abortions now account for over half of U.S. abortions.
Data from Congress.gov
Public Opinions
Community submissions related to this bill.
No public opinions yet. Be the first to submit one for this bill.
Related Bills in Health
Empowering Patient Choice of Medical Care Act
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means
To amend the Federal Food, Drug, and Cosmetic Act to exempt the premium cigar industry from certain regulations.
Referred to the House Committee on Energy and Commerce.
Anti-Racism in Public Health Act of 2025
Referred to the House Committee on Energy and Commerce.
SOAR Act of 2025
Read twice and referred to the Committee on Finance.